Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $20.4500 (1.79%) ($20.1600 - $20.9000) on Mon. Jul. 6, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.44% (three month average) | RSI | 65 | Latest Price | $20.4500(1.79%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 2% a day on average for past five trading days. | Weekly Trend | TGTX advances 3.8% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(64%) ARKG(59%) ARKK(56%) IWO(56%) IBB(55%) | Factors Impacting TGTX price | TGTX will decline at least -3.22% in a week (0% probabilities). VIXM(-35%) VXX(-33%) UUP(-18%) DRIV(-4%) XLC(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.22% (StdDev 6.44%) | Hourly BBV | 0 () | Intraday Trend | -1.8% | | | |
|
5 Day Moving Average | $19.78(3.39%) | 10 Day Moving Average | $19.41(5.36%) | 20 Day Moving Average | $18.73(9.18%) | To recent high | -6.4% | To recent low | 113.9% | Market Cap | $2.59b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |